Idexx Laboratories is listed on the national NASDAQ GS market as 09.11.2018, 06:20 clock with 208.97 USD. Idexx Laboratories is part of the "Sanitary equipment" segment.
How the Idexx laboratories currently need to evaluate the results of multi-stage analysis. We have selected 7 categories, each of which leads to the result "buy", "keep" or "sell". These results are finally consolidated for the overall result.
1. Fundamental: the P / E ratio (P / E ratio) is an important measure of the way in which the profit power and performance of an enterprise are compared to one or more others. At Idexx Laboratories, the current PER is 44.58. Comparable companies in the medical equipment and devices sector have an average P / E of 72.16. Idexx Laboratories is underestimated from a fundamental point of view today. The stock receives from the publishers of this category so a "buy" estimate.
2. Relative Strength Index: In order to assess whether a stock is currently "overbought" or "oversold", movements up and down over time can be correlated. This provides the so-called Relative Strength Index (RSI), an indicator of technical analysis widely used in the financial market. We now evaluate Idexx Laboratories on the shorter-term RSI of the last 7 days and the slightly longer RSI on a 25-day basis. First of all, the 7-day RSI: currently it stands at 51.31 points, which means that the stock of Idexx Laboratories is neither overbought nor sold. As a result, he receives a "wait" rating. Now for the RSI25: Idexx Laboratories is neither overbought nor sold on a 25-day basis (value: 60.14). That's why the stock also gets a "Hold" rating for the RSI25. This gives Idexx Laboratories a "Hold" score for this point in our analysis.
3. Comparison of the share price sector: the stock achieved a return of 33.51% last year. Idexx Laboratories is 9.97 percent above average (23.54 percent) compared to health care stocks. The average annual return on the securities of the "Medical equipment and devices" industry is 18.64%. Idexx Laboratories is currently 14.88% higher than this value. Due to the outperformance, we estimate the overall share at this level with a "buy".